Table 4. Target to muscle and target to blood ratios of 99mTc(I)-estradiol-pyridin-2-yl hydrazine derivative.
99mTc(I)-estradiol-pyridin-2-yl hydrazine uptake was determined in ovariectomized female athymic NCr-nu/nu mice bearing MCF-7 human breast adenocarcinoma tumors. Data represent the mean value ± SEM from at least 4 determinations.
| Target/Background | 1 hour PI | 3 hour PI | 3 hour PI (block)a,b | 24 hour PI |
|---|---|---|---|---|
| Uterus/Muscle | 6.44 ± 0.81 | 5.21 ± 1.12 | 3.32 ± 0.46 | 3.58 ± 0.47 |
| Mammary/Muscle | 7.05 ± 0.87 | 6.74 ± 1.21 | 2.45 ± 0.51 | 3.50 ± 0.82 |
| MCF-7 tumor/Muscle | 4.75 ± 0.43 | 5.67 ± 1.06 | 2.64 ± 0.53 | 3.54 ± 0.26 |
| Uterus/Blood | 0.57 ± 0.02 | 0.34 ± 0.04 | 0.24 ± 0.02 | 1.02 ± 0.16 |
| Mammary/Blood | 0.62 ± 0.05 | 0.43 ± 0.05 | 0.18 ± 0.02 | 0.91 ± 0.11 |
| MCF-7 tumor/Blood | 0.43 ± 0.07 | 0.35 ± 0.05 | 0.19 ± 0.02 | 1.03 ± 0.19 |
a
All ratios at 3 hr PI are significantly different ( p < 0.05) from the ratios at 3 hr PI when the radiotracer was co-injected with 5 μg of 17ß-E2 for blocking the receptor.
b
Receptor blocking studies were performed by co-injecting 5 μg 17β-estradiol with the radiotracer.